{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lu Y"],"funding":["NIH HHS"],"pagination":["530"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6345854"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(1)"],"pubmed_abstract":["Cell culture and protein target-based compound screening strategies, though broadly utilized in selecting candidate compounds, often fail to eliminate candidate compounds with non-target effects and/or safety concerns until late in the drug developmental process. Phenotype screening using intact research animals is attractive because it can help identify small molecule candidate compounds that have a high probability of proceeding to clinical use. Most FDA approved, first-in-class small molecules were identified from phenotypic screening. However, phenotypic screening using rodent models is labor intensive, low-throughput, and very expensive. As a novel alternative for small molecule screening, we have been developing gene expression disease profiles, termed the Transcriptional Disease Sig"],"journal":["Scientific reports"],"pubmed_title":["Application of the Transcriptional Disease Signature (TDSs) to Screen Melanoma-Effective Compounds in a Small Fish Model."],"pmcid":["PMC6345854"],"funding_grant_id":["R24 OD011198","R24 OD011120","R24 OD018555"],"pubmed_authors":["Regneri J","Schartl M","Savage M","Lu Y","Boswell M","Klotz B","Mendoza C","Walter RB","Boswell W","Kneitz S","Warren WC","Postlethwait J"],"additional_accession":[]},"is_claimable":false,"name":"Application of the Transcriptional Disease Signature (TDSs) to Screen Melanoma-Effective Compounds in a Small Fish Model.","description":"Cell culture and protein target-based compound screening strategies, though broadly utilized in selecting candidate compounds, often fail to eliminate candidate compounds with non-target effects and/or safety concerns until late in the drug developmental process. Phenotype screening using intact research animals is attractive because it can help identify small molecule candidate compounds that have a high probability of proceeding to clinical use. Most FDA approved, first-in-class small molecules were identified from phenotypic screening. However, phenotypic screening using rodent models is labor intensive, low-throughput, and very expensive. As a novel alternative for small molecule screening, we have been developing gene expression disease profiles, termed the Transcriptional Disease Sig","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Jan","modification":"2025-04-26T08:55:56.378Z","creation":"2019-03-26T22:41:53Z"},"accession":"S-EPMC6345854","cross_references":{"pubmed":["30679619"],"doi":["10.1038/s41598-018-36656-x"]}}